University of Oulu

Seliger B, Al-Samadi A, Yang B, Salo T and Wickenhauser C (2022) In vitro models as tools for screening treatment options of head and neck cancer. Front. Med. 9:971726. doi: 10.3389/fmed.2022.971726.

In vitro models as tools for screening treatment options of head and neck cancer

Saved in:
Author: Seliger, Barbara1,2; Al-Samadi, Ahmed3,4; Yang, Bo1;
Organizations: 1Institute of Medical Immunology, Martin Luther University Halle-Wittenberg, Halle, Germany
2Fraunhofer Institute for Cell Therapy and Immunology, Leipzig, Germany
3Department of Oral and Maxillofacial Diseases, Clinicum, Faculty of Medicine, University of Helsinki, Helsinki, Finland
4Translational Immunology Research Program, Research Program Unit, University of Helsinki, Helsinki, Finland
5Cancer Research and Translational Medicine Research Unit, University of Oulu, Oulu, Finland
6Medical Research Center Oulu, Oulu University Hospital, University of Oulu, Oulu, Finland
7Institute of Pathology, Martin Luther University Halle-Wittenberg, Halle, Germany
Format: article
Version: published version
Access: open
Online Access: PDF Full Text (PDF, 2.2 MB)
Persistent link:
Language: English
Published: Frontiers Media, 2022
Publish Date: 2023-06-02


Various in vitro models using primary and established 2- and 3-dimensional cultures, multicellular tumor spheroids, standardized tumor slice cultures, tumor organoids, and microfluidic systems obtained from tumor lesions/biopsies of head and neck cancer (HNC) have been employed for exploring and monitoring treatment options. All of these in vitro models are to a different degree able to capture the diversity of tumors, recapitulate the disease genetically, histologically, and functionally and retain their tumorigenic potential upon xenotransplantation. The models were used for the characterization of the malignant features of the tumors and for in vitro screens of drugs approved for the treatment of HNC, including chemotherapy and radiotherapy as well as recently developed targeted therapies and immunotherapies, or for novel treatments not yet licensed for these tumor entities. The implementation of the best suitable model will enlarge our knowledge of the oncogenic properties of HNC, expand the drug repertoire and help to develop individually tailored treatment strategies resulting in the translation of these findings into the clinic. This review summarizes the different approaches using preclinical in vitro systems with their advantages and disadvantages and their implementation as preclinical platforms to predict disease course, evaluate biomarkers and test therapy efficacy.

see all

Series: Frontiers in medicine
ISSN: 2296-858X
ISSN-E: 2296-858X
ISSN-L: 2296-858X
Volume: 9
Article number: 971726
DOI: 10.3389/fmed.2022.971726
Type of Publication: A2 Review article in a scientific journal
Field of Science: 3122 Cancers
Copyright information: © 2022 Seliger, Al-Samadi, Yang, Salo and Wickenhauser. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.